Publications

Acknowledgement of ICCB-L in Publications

Researchers using the services of ICCB-L staff or equipment agree to acknowledge the support of 'ICCB-Longwood Screening Facility at Harvard Medical School' in publications arising from your use of the facility. If an ICCB-L member has made an important intellectual contribution to the project, as determined by generally accepted criteria for academic collaborations, then that person should be considered for authorship on the publication. If your project was supported by a grant that also directly supports the ICCB-L, please consult the ICCB-L Director regarding the appropriate grant citation. Please notify Jen Smith upon public release of your publication.

Sort & Filters

Filters

Year of Publication

589 results

589 results

2024

Design and Construction of Synthetic Biology Tools for Sustainable Lanthanide Extraction.
[United States -- Massachusetts]: Harvard University; 2024. p. 135+.
Design and Construction of Synthetic Biology Tools for Sustainable Lanthanide Extraction.
[United States -- Massachusetts]: Harvard University; 2024. p. 135+.
BF170 hydrochloride enhances the emergence of hematopoietic stem and progenitor cells.
2024;151(13):dev202476+.
BF170 hydrochloride enhances the emergence of hematopoietic stem and progenitor cells.
2024;151(13):dev202476+.
A conserved transcription factor regulatory program promotes tendon fate.
Developmental Cell. Elsevier; 2024;59(23):3106–3123.e12,.
A conserved transcription factor regulatory program promotes tendon fate.
Developmental Cell. Elsevier; 2024;59(23):3106–3123.e12,.

2023

Du T, Song Y, Ray A, Wan X, Yao, Samur M, Shen C, Penailillo J, Sewastianik T, Tai YT, Fulciniti, Munshi N, Wu, Carrasco R, Chauhan D, Anderson K. Ubiquitin receptor PSMD4/Rpn10 is a novel therapeutic target in multiple myeloma.
Blood. 2023;(Jan 11).
Du T, Song Y, Ray A, Wan X, Yao, Samur M, Shen C, Penailillo J, Sewastianik T, Tai YT, Fulciniti, Munshi N, Wu, Carrasco R, Chauhan D, Anderson K. Ubiquitin receptor PSMD4/Rpn10 is a novel therapeutic target in multiple myeloma.
Blood. 2023;(Jan 11).
Ryan C, Brander D, Barr P, Tyekucheva S, Hackett L, Collins M, Fernandes S, Ren Y, Zhou Y, McDonough M, Walker H, McEwan M, Abramson J, Jacobsen E, LaCasce A, Fisher D, Brown J, Davids M. A phase 1b study of ibrutinib in combination with obinutuzumab in patients with relapsed or refractory chronic lymphocytic leukemia.
Leukemia. 2023;(Jan 30).
Ryan C, Brander D, Barr P, Tyekucheva S, Hackett L, Collins M, Fernandes S, Ren Y, Zhou Y, McDonough M, Walker H, McEwan M, Abramson J, Jacobsen E, LaCasce A, Fisher D, Brown J, Davids M. A phase 1b study of ibrutinib in combination with obinutuzumab in patients with relapsed or refractory chronic lymphocytic leukemia.
Leukemia. 2023;(Jan 30).
Chew K, Lee, Ozonoff A, Smith J, Levy O, Dowling D, Haren S. A protocol for high-throughput screening for immunomodulatory compounds using human primary cells.
STAR Protoc. 2023;4(3):102405.
Chew K, Lee, Ozonoff A, Smith J, Levy O, Dowling D, Haren S. A protocol for high-throughput screening for immunomodulatory compounds using human primary cells.
STAR Protoc. 2023;4(3):102405.
Yang JH, Petty C, Dixon-McDougall T, Lopez M, Tyshkovskiy A, Maybury-Lewis S, Tian X, Ibrahim N, Chen Z, Griffin P, Arnold M, Li J, Martinez O, Behn A, Rogers-Hammond R, Angeli S, Gladyshev V, Sinclair D. Chemically induced reprogramming to reverse cellular aging.
2023;15(13):5966–5989.
Yang JH, Petty C, Dixon-McDougall T, Lopez M, Tyshkovskiy A, Maybury-Lewis S, Tian X, Ibrahim N, Chen Z, Griffin P, Arnold M, Li J, Martinez O, Behn A, Rogers-Hammond R, Angeli S, Gladyshev V, Sinclair D. Chemically induced reprogramming to reverse cellular aging.
2023;15(13):5966–5989.
Ralvenius W, Mungenast A, Woolf H, Huston M, Gillingham T, Godin S, Penney J, Cam H, Gao F, Fernandez C, Czako B, Lightfoot Y, Ray W, Beckmann A, Goate A, Marcora E, Romero-Molina C, Ayata P, Schaefer A, Gjoneska E, Tsai LH. A novel molecular class that recruits HDAC/MECP2 complexes to PU.1 motifs reduces neuroinflammation.
J Exp Med. 2023;220(11):e20222105.
Ralvenius W, Mungenast A, Woolf H, Huston M, Gillingham T, Godin S, Penney J, Cam H, Gao F, Fernandez C, Czako B, Lightfoot Y, Ray W, Beckmann A, Goate A, Marcora E, Romero-Molina C, Ayata P, Schaefer A, Gjoneska E, Tsai LH. A novel molecular class that recruits HDAC/MECP2 complexes to PU.1 motifs reduces neuroinflammation.
J Exp Med. 2023;220(11):e20222105.
Quek R, Hardy K, Walker S, Nguyen D, Magalhães T, Salic, Gopalakrishnan S, Silver P, Mitchison T. Screen for Modulation of Nucleocapsid Protein Condensation Identifies Small Molecules with Anti-Coronavirus Activity.
ACS Chem Biol. 2023;18(3):583–594.
Quek R, Hardy K, Walker S, Nguyen D, Magalhães T, Salic, Gopalakrishnan S, Silver P, Mitchison T. Screen for Modulation of Nucleocapsid Protein Condensation Identifies Small Molecules with Anti-Coronavirus Activity.
ACS Chem Biol. 2023;18(3):583–594.
Park D, Nguyen S, Isenhart R, Shah P, Kim W, Barnett R, Chandra A, Luppino J, Harke J, Wai M, Walsh P, Abdill R, Yang R, Lan Y, Yoon S, Yunker R, Kanemaki M, Vahedi G, Phillips-Cremins J, Jain R, Joyce E. High-throughput Oligopaint screen identifies druggable 3D genome regulators.
Nature. 2023;620:209–217.
Park D, Nguyen S, Isenhart R, Shah P, Kim W, Barnett R, Chandra A, Luppino J, Harke J, Wai M, Walsh P, Abdill R, Yang R, Lan Y, Yoon S, Yunker R, Kanemaki M, Vahedi G, Phillips-Cremins J, Jain R, Joyce E. High-throughput Oligopaint screen identifies druggable 3D genome regulators.
Nature. 2023;620:209–217.
Sabag-Daigle A, Boulanger E, Thirugnanasambantham P, Law J, Bogard A, Behrman E, Gopalan V, Ahmer B. Identification of Small-Molecule Inhibitors of the Salmonella FraB Deglycase Using a Live-Cell Assay.
Microbiol Spectr. 2023;11(2):e0460622.
Sabag-Daigle A, Boulanger E, Thirugnanasambantham P, Law J, Bogard A, Behrman E, Gopalan V, Ahmer B. Identification of Small-Molecule Inhibitors of the Salmonella FraB Deglycase Using a Live-Cell Assay.
Microbiol Spectr. 2023;11(2):e0460622.
Sadeeshkumar H, Balaji A, Sutherland A, Mootien, Anthony K, Breaker R. Screening for small molecule inhibitors of SAH nucleosidase using an SAH riboswitch.
Anal Biochem. 2023;666:115047.
Sadeeshkumar H, Balaji A, Sutherland A, Mootien, Anthony K, Breaker R. Screening for small molecule inhibitors of SAH nucleosidase using an SAH riboswitch.
Anal Biochem. 2023;666:115047.